Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morning brief

- PMLiVE

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly's drug beat semaglutide 1mg on multiple measures including weight loss

Gene Editing and Precision Medicine: The Future of Healthcare?

Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...

Impetus Digital

- PMLiVE

Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy

Project will aim to discover and develop a gene therapy for sickle cell disease

- PMLiVE

bluebird bio temporarily suspends trials of sickle cell gene therapy LentiGlobin

Company will also suspend marketing of beta-thalassemia gene therapy Zynteglo

- PMLiVE

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

Sandoz, the generics division of Novartis, will pay $350m upfront for three established brands

- PMLiVE

NICE turns down bluebird bio’s gene therapy Zynteglo

Draft guidance does not recommend routine NHS funding for beta thalassaemia treatment

- PMLiVE

After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

Thanks to advances in technology and new commercial viability, cell and gene therapy is finally coming of age

- PMLiVE

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Acquisition includes a number of candidates for neurodegenerative diseases

- PMLiVE

Novo Nordisk launches late-stage study in Alzheimer’s disease

Study will evaluate oral semaglutide in neurodegenerative disease

Bayer symbol

Bayer strengthens cell and gene therapy focus with new platform

Platform builds on previous acquisition deals for AskBio and BlueRock

- PMLiVE

UCB boosts gene therapy offering with a pair of new deals

Company will collaborate with Lacerta Therapeutics and acquire Handl Therapeutics

- PMLiVE

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Danish pharma will acquire all outstanding shares in Emisphere

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links